This invention is directed to sorbitol dehydrogenase inhibitory compounds of
formula I
##STR1##
wherein R1, R2 and R3 are as defined in
the specification. This invention is also directed to pharmaceutical compositions
containing these compounds and to methods of treating or preventing diabetic complications,
particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy,
diabetic macroangiopathy, diabetic cardiomyopathy and foot ulcers. This invention
is also directed to pharmaceutical compositions comprising a combination of a compound
of formula I of the present invention with a second pharmaceutical agent, including
an aldose reductase inhibitor, a sodium hydrogen ion exchange inhibitor, a glycogen
phosphorylase inhibitor, a selective serotonin reuptake inhibitor, a 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor, an angiotensin converting enzyme inhibitor, a thiazolidinedione
antidiabetic agent, an angiotensin II receptor antagonist, a -aminobutyric
acid agonist, a phosphodiesterase type 5 inhibitor, an adenosine agonist, and a
CETP inhibitor and to methods of using these compositions.
